The Board of Directors of the Company at its meeting held today, i.e. April 24, 2025 have considered and approved inter alia the following: 1. The Letter of Offer, Abridged Letter of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.9 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Remedium Lifecare Ltd's Board of Directors met on April 24, 2025 and approved the Letter of Offer, Abridged Letter of Offer, Rights Entitlement Letter, Application Form, and related documents for a Rights Issue to be filed with BSE. The Rights Issue opens on April 30, 2025 and closes on May 14, 2025. Eligible equity shareholders as on the Record Date will receive Rights Entitlements credited to their demat accounts under ISIN INE549520010 prior to the issue opening. The company trades under Scrip Code 539561 (REMLIFE) on BSE. Note: The headline refers to Supha Pharmachem Ltd, but the document body is from Remedium Lifecare Ltd.
Existing shareholders will have the opportunity (but not obligation) to subscribe to additional shares in proportion to their holdings, which could dilute equity if not fully subscribed. The exact ratio and price are not disclosed in this filing, so investors should await the Letter of Offer for subscription terms.